141 related articles for article (PubMed ID: 38561505)
1. The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
Wei Y; Chen Z; Li Y; Song K
Oncogene; 2024 May; 43(20):1565-1578. PubMed ID: 38561505
[TBL] [Abstract][Full Text] [Related]
2. SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52.
Diao Y; Li Y; Wang Z; Wang S; Li P; Kong B
Cell Death Dis; 2022 Feb; 13(2):179. PubMed ID: 35210412
[TBL] [Abstract][Full Text] [Related]
3. TRIM24 aggravates the progression of ovarian cancer through negatively regulating FOXM1 level.
Zhou HE; Pan SS; Han H
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10647-10656. PubMed ID: 31858531
[TBL] [Abstract][Full Text] [Related]
4. Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2.
Wang S; Wang Z; Li J; Qin J; Song J; Li Y; Zhao L; Zhang X; Guo H; Shao C; Kong B; Liu Z
Cell Death Dis; 2021 Mar; 12(4):294. PubMed ID: 33731694
[TBL] [Abstract][Full Text] [Related]
5. YTHDC1-dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple-negative breast cancer.
Shen X; Zhong J; Yu P; Liu F; Peng H; Chen N
Cancer Sci; 2024 Jun; 115(6):1881-1895. PubMed ID: 38566554
[TBL] [Abstract][Full Text] [Related]
6. Transformer 2β regulates the alternative splicing of cell cycle regulatory genes to promote the malignant phenotype of ovarian cancer.
Zhou T; Fu P; Chen D; Liu R
Oncol Res; 2023; 31(5):769-785. PubMed ID: 37547760
[TBL] [Abstract][Full Text] [Related]
7. WBP11 is required for splicing the TUBGCP6 pre-mRNA to promote centriole duplication.
Park EM; Scott PM; Clutario K; Cassidy KB; Zhan K; Gerber SA; Holland AJ
J Cell Biol; 2020 Jan; 219(1):. PubMed ID: 31874114
[TBL] [Abstract][Full Text] [Related]
8. Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention.
Wang X; Han M; Wang S; Sun Y; Zhao W; Xue Z; Liang X; Huang B; Li G; Chen A; Li X; Wang J
Theranostics; 2022; 12(12):5451-5469. PubMed ID: 35910786
[No Abstract] [Full Text] [Related]
9. AKT1 phosphorylates RBM17 to promote Sox2 transcription by modulating alternative splicing of FOXM1 to enhance cancer stem cell properties in colorectal cancer cells.
Fu Y; Bai C; Wang S; Chen D; Zhang P; Wei H; Rong F; Zhang C; Chen S; Wang Z
FASEB J; 2023 Jan; 37(1):e22707. PubMed ID: 36520054
[TBL] [Abstract][Full Text] [Related]
10. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.
Chan DW; Hui WW; Wang JJ; Yung MM; Hui LM; Qin Y; Liang RR; Leung TH; Xu D; Chan KK; Yao KM; Tsang BK; Ngan HY
Oncogene; 2017 Mar; 36(10):1404-1416. PubMed ID: 27593933
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer.
Yang H; Sui L; Cai C; Chu H; Diao Y
J Ovarian Res; 2024 Feb; 17(1):34. PubMed ID: 38317200
[TBL] [Abstract][Full Text] [Related]
13. OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer.
Wang Y; Zhou X; Xu M; Weng W; Zhang Q; Yang Y; Wei P; Du X
Oncotarget; 2016 Jun; 7(24):36681-36697. PubMed ID: 27167337
[TBL] [Abstract][Full Text] [Related]
14. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
Li Y; Chen Z; Peng J; Yuan C; Yan S; Yang N; Li P; Kong B
Oncogene; 2023 Jul; 42(31):2386-2401. PubMed ID: 37391593
[TBL] [Abstract][Full Text] [Related]
15. The DNA replication licensing factor miniature chromosome maintenance 7 is essential for RNA splicing of epidermal growth factor receptor, c-Met, and platelet-derived growth factor receptor.
Chen ZH; Yu YP; Michalopoulos G; Nelson J; Luo JH
J Biol Chem; 2015 Jan; 290(3):1404-11. PubMed ID: 25425645
[TBL] [Abstract][Full Text] [Related]
16. PRMT5 promotes colorectal cancer growth by interaction with MCM7.
Li X; Wang X; Zhao J; Wang J; Wu J
J Cell Mol Med; 2021 Apr; 25(7):3537-3547. PubMed ID: 33675123
[TBL] [Abstract][Full Text] [Related]
17. Phospholipase PLCE1 Promotes Transcription and Phosphorylation of MCM7 to Drive Tumor Progression in Esophageal Cancer.
Shi Q; Xu G; Jiang Y; Yang J; Han X; Wang Q; Li Y; Zhang Z; Wang K; Peng H; Chen F; Ma Y; Zhao L; Chen Y; Liu Z; Yang L; Jia X; Wen T; Tong Z; Cui X; Li F
Cancer Res; 2024 Feb; 84(4):560-576. PubMed ID: 38117512
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT
Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405
[TBL] [Abstract][Full Text] [Related]
19. TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing.
He Y; OuYang Z; Liu W; Chen Y; Zhang Q
Oncogene; 2023 Jan; 42(1):49-61. PubMed ID: 36369320
[TBL] [Abstract][Full Text] [Related]
20. MFAP2 aggravates tumor progression through activating FOXM1/β-catenin-mediated glycolysis in ovarian cancer.
Zhao LQ; Sun W; Zhang P; Gao W; Fang CY; Zheng AW
Kaohsiung J Med Sci; 2022 Aug; 38(8):772-780. PubMed ID: 35546486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
